InsiderTrades.com logo
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.

LXEO Insider Trading

Insider Ownership Percentage: 4.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $636,438.50

Lexeo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Lexeo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lexeo Therapeutics Share Price & Price History

Current Price: $6.28
Price Change: ▲ Price Increase of +0.24 (3.97%)
As of 12/20/2024 06:16 PM ET

This chart shows the closing price history over time for LXEO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
From Behind the Markets   |   Ad
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Click here for the ticker >>>

Lexeo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/10/2024Richard Nolan TownsendCEOSell2,500$8.20$20,500.00120,695View SEC Filing Icon  
11/11/2024Richard Nolan TownsendCEOSell2,500$7.82$19,550.00120,695View SEC Filing Icon  
10/10/2024Richard Nolan TownsendCEOSell5,000$8.10$40,500.00120,695View SEC Filing Icon  
9/10/2024Richard Nolan TownsendCEOSell5,000$10.65$53,250.00120,695View SEC Filing Icon  
8/12/2024Richard Nolan TownsendCEOSell5,000$11.53$57,650.00120,695View SEC Filing Icon  
7/10/2024Richard Nolan TownsendCEOSell26,969$16.50$444,988.50148,726View SEC Filing Icon  
11/7/2023Fund Vi L.P. OmegaMajor ShareholderBuy454,545$11.00$4,999,995.002,157,623View SEC Filing Icon  
See Full Table
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.

SEC Filings (Institutional Ownership Changes) for Lexeo Therapeutics (NASDAQ:LXEO)

60.67% of Lexeo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LXEO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lexeo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
12/13/2024Exome Asset Management LLC88,148$0.80M0.5%N/A0.267%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC50,210$0.45M0.0%+162.2%0.152%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC553,247$5M0.0%+86.5%1.673%Search for SEC Filing on Google Icon
11/15/2024Frazier Life Sciences Management L.P.1,250,786$11.31M0.5%N/A3.783%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC50,210$0.45M0.0%+162.2%0.152%Search for SEC Filing on Google Icon
11/15/2024Jane Street Group LLC35,677$0.32M0.0%+33.3%0.108%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP51,892$0.47M0.0%+134.8%0.157%Search for SEC Filing on Google Icon
11/15/2024State Street Corp253,946$2.30M0.0%+29.4%0.768%Search for SEC Filing on Google Icon
11/15/2024RA Capital Management L.P.546,554$4.94M0.1%-18.8%1.653%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.370,407$3.35M0.0%N/A1.120%Search for SEC Filing on Google Icon
11/15/2024Polar Asset Management Partners Inc.59,800$0.54M0.0%-8.4%0.181%Search for SEC Filing on Google Icon
11/15/2024Ikarian Capital LLC257,216$2.33M0.3%N/A0.778%Search for SEC Filing on Google Icon
11/15/2024Jacobs Levy Equity Management Inc.30,346$0.27M0.0%N/A0.092%Search for SEC Filing on Google Icon
11/15/2024Janus Henderson Group PLC3,763,195$34M0.0%+18.9%11.383%Search for SEC Filing on Google Icon
11/14/2024PDT Partners LLC26,608$0.24M0.0%N/A0.080%Search for SEC Filing on Google Icon
11/14/2024Braidwell LP728,777$6.59M0.2%-47.3%2.204%Search for SEC Filing on Google Icon
11/14/2024Eventide Asset Management LLC1,855,986$16.78M0.3%-44.9%5.614%Search for SEC Filing on Google Icon
11/14/2024Verition Fund Management LLC777,320$7.03M0.0%+84.5%2.351%Search for SEC Filing on Google Icon
11/14/2024Vestal Point Capital LP850,000$7.68M0.6%+1.2%2.571%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC14,223$0.13M0.0%+121.5%0.043%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets5,541$50K0.0%+184.2%0.017%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.63,874$0.58M0.0%+107.0%0.193%Search for SEC Filing on Google Icon
10/24/2024Novo Holdings A S1,122,581$10.15M0.5%-22.6%3.407%Search for SEC Filing on Google Icon
10/23/2024Values First Advisors Inc.7,446$67K0.0%N/A0.023%Search for SEC Filing on Google Icon
8/20/2024Novo Holdings A S1,450,500$23.27M1.2%-11.5%4.403%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers13,357$0.21M0.0%+37.3%0.041%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp31,806$0.51M0.0%+12.3%0.097%Search for SEC Filing on Google Icon
5/17/2024RA Capital Management L.P.660,938$10.36M0.1%N/A2.006%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.801,716$12.57M0.3%+32.9%2.434%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC2,540,785$39.80M0.0%+9.0%7.713%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.5,053$79K0.0%N/A0.015%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.481,755$7.55M0.0%+15.8%1.462%Search for SEC Filing on Google Icon
5/1/2024BNP Paribas Financial Markets4,781$75K0.0%N/A0.015%Search for SEC Filing on Google Icon
4/29/2024Cornell University126,258$1.98M30.0%N/A0.383%Search for SEC Filing on Google Icon
2/20/2024Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268%Search for SEC Filing on Google Icon
2/15/2024Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096%Search for SEC Filing on Google Icon
2/15/2024Blackstone Inc.696,110$9.34M0.0%N/A2.612%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More on Lexeo Therapeutics

Today's Range

Now: $6.28
Low: $5.81
High: $6.34

50 Day Range

MA: $7.91
Low: $6.00
High: $11.12

52 Week Range

Now: $6.28
Low: $5.77
High: $22.33

Volume

598,933 shs

Average Volume

253,012 shs

Market Capitalization

$207.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lexeo Therapeutics?

Lexeo Therapeutics' top insider investors include:
  1. Fund Vi LP Omega (Major Shareholder)
  2. Richard Nolan Townsend (CEO)
Learn More about top insider investors at Lexeo Therapeutics.

Who are the major institutional investors of Lexeo Therapeutics?

Lexeo Therapeutics' top institutional shareholders include:
  1. Janus Henderson Group PLC — 11.38%
  2. Eventide Asset Management LLC — 5.61%
  3. Frazier Life Sciences Management L.P. — 3.78%
  4. Novo Holdings A S — 3.41%
  5. Vestal Point Capital LP — 2.57%
  6. Verition Fund Management LLC — 2.35%
Learn More about top institutional investors of Lexeo Therapeutics stock.

Which institutional investors are selling Lexeo Therapeutics stock?

Within the previous quarter, LXEO stock was sold by these institutional investors:
  1. Eventide Asset Management LLC
  2. Braidwell LP
  3. Novo Holdings A S
  4. RA Capital Management L.P.
  5. Polar Asset Management Partners Inc.

Which institutional investors are buying Lexeo Therapeutics stock?

In the last quarter, LXEO stock was purchased by institutional investors including:
  1. Frazier Life Sciences Management L.P.
  2. Janus Henderson Group PLC
  3. Point72 Asset Management L.P.
  4. Verition Fund Management LLC
  5. Ikarian Capital LLC
  6. Geode Capital Management LLC
  7. Exome Asset Management LLC
  8. State Street Corp
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.